More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.89B
EPS
-1.73
P/E ratio
--
Price to sales
862.66
Dividend yield
--
Beta
1.083799
Previous close
$18.08
Today's open
$18.11
Day's range
$17.17 - $18.26
52 week range
$15.34 - $27.30
show more
CEO
Ryan J. Watts
Employees
503
Headquarters
South San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
160290546
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • 18 hours ago

Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
Denali Therapeutics NASDAQ: DNLI is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe disease and Alzheimer's disease.
MarketBeat • Nov 13, 2026

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 14, 2026

Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)
I initiate Denali Therapeutics at Buy, as the Avlayah launch has validated the TransportVehicle platform and turned DNLI into a commercial-stage story. Q3 Avlayah sales of $17.8M crushed the $10-12M guide, and Q4 guidance of $30-32M implies 65%+ sequential growth. DNL126 in Sanfilippo A is heading toward a 2027 accelerated-approval BLA and reuses the Avlayah commercial playbook almost one-for-one.
Seeking Alpha • Nov 13, 2026

DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
Zacks Investment Research • Nov 5, 2026

Denali Therapeutics Q3 Earnings Call Highlights
Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participants to commercial therapy supported a faster-than-expected launch.
MarketBeat • Nov 4, 2026

Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 million AVLAYAH recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation Zafinofusp alfa advancing as Denali's second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA) Five TransportVehicle™ (TV) programs expected to generate data in 2027: zafinofusp alfa (ETV:SGSH), DNL593 (PTV:PGRN), DNL628 (OTV:MAPT), DNL921 (ATV:Abeta) and DNL952 (ETV:GAA) Q3 2026 net income of $70.1 million included a one-time $194.0 million net gain on the sale of a Priority Review Voucher, bringing cash, cash equivalents and marketable securities to $1.0 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
GlobeNewsWire • Nov 3, 2026

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation. AVLAYAH is the first biologic approved by the U.S. Food and Drug Administration (FDA) that is specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy that received FDA accelerated approval in March 2026 for the treatment of neurologic manifestations of a rare neurodegenerative disease called Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.
GlobeNewsWire • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Denali Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.